Literature DB >> 11422007

Quinapril and its metabolite quinaprilat in human milk.

E J Begg1, R A Robson, S J Gardiner, L J Hudson, P A Reece, S C Olson, E L Posvar, A J Sedman.   

Abstract

AIMS: To measure the milk to plasma ratio (M/P) of quinapril and its active metabolite quinaprilat in lactating mothers and to assess likely infant exposure.
METHODS: A single dose of quinapril 20 mg was administered to six healthy mothers who had been breastfeeding their infants for at least 2 weeks. Blood was sampled for the measurement of quinapril and quinaprilat at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h. Milk was collected for measurement of quinapril and quinaprilat concentrations over the periods -4-0, 0-4, 4-8, 8-12, 12-18, 18-24 h. The areas under the plasma and milk concentration-time curves were estimated and an M/P ratio derived for both quinapril and quinaprilat.
RESULTS: The M/P ratio for quinapril was 0.12 (95% CI 0.09,0.14). No quinapril was detected in milk after 4 h. No quinaprilat was detected in any of the milk samples. The estimated 'dose' of quinapril that would be received by the infant was 1.6% (95% CI 1.0,2.2) of the maternal dose, adjusted for respective weights.
CONCLUSIONS: Quinapril appears to be 'safe' during breastfeeding according to conventional criteria, although as always, the risk:benefit ratio should be considered when it is to be given to a nursing mother.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422007      PMCID: PMC2014479          DOI: 10.1046/j.1365-2125.2001.01327.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  The excretion of enalapril and enalaprilat in human breast milk.

Authors:  C W Redman; J G Kelly; W D Cooper
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Enalapril treatment of a nursing with slightly impaired renal function.

Authors:  K Huttunen; C Grönhagen-Riska; F Fyhrquist
Journal:  Clin Nephrol       Date:  1989-05       Impact factor: 0.975

3.  Determination of quinapril and its active metabolite in human plasma and urine by gas chromatography with electron-capture detection.

Authors:  J J Ferry; A M Horvath; M Easton-Taylor; R D Toothaker; W A Colburn
Journal:  J Chromatogr       Date:  1987-10-09

Review 4.  Quinapril. A review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders.

Authors:  A N Wadworth; R N Brogden
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

5.  Captopril in human blood and breast milk.

Authors:  R G Devlin; P M Fleiss
Journal:  J Clin Pharmacol       Date:  1981 Feb-Mar       Impact factor: 3.126

  5 in total
  4 in total

Review 1.  Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  Christine R Culy; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Pregnancy and Glomerular Disease: A Systematic Review of the Literature with Management Guidelines.

Authors:  Kimberly Blom; Ayodele Odutayo; Kate Bramham; Michelle A Hladunewich
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-18       Impact factor: 8.237

3.  Perindopril in Breast Milk and Determination of Breastfed Infant Exposure: A Prospective Observational Study.

Authors:  Catherine Leggett; Ei Mon Phyo Lwin; Usha Ritchie; Yunmei Song; Jacobus P Gerber; Sean Turner; William M Hague; Michael Stark; Richard Upton; Sanjay Garg
Journal:  Drug Des Devel Ther       Date:  2020-03-02       Impact factor: 4.162

Review 4.  The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach.

Authors:  Sahar Najafi; Elham Rajaei; Rezvan Moallemian; Forough Nokhostin
Journal:  Clin Rheumatol       Date:  2020-09-03       Impact factor: 3.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.